|Mr. John A. Roberts M.B.A., MBA||Pres, CEO & Director||597.69k||N/A||1959|
|Mr. Yung-Ping Yeh M.B.A., M.S., P.M.P.||Co-Founder & Director||351.45k||N/A||1976|
|Mr. Andrew D.C. LaFrence CPA, CPA||Chief Financial Officer||355.34k||N/A||1963|
|Dr. Ralf Brandt Ph.D.||Pres of Discovery & Early Devel. Services||445.48k||N/A||1963|
|Dr. Robert Thomas Fremeau Jr., Ph.D.||Chief Scientific Officer||N/A||N/A||1955|
|Dr. Robert J. Petcavich Ph.D.||Chief Science Advisor & Director||N/A||N/A||1954|
|Dr. Barb Jones Ph.D.||Sr. VP of Scientific Operations & Regulatory Affairs||N/A||N/A||N/A|
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
Vyant Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.